Search

Displaying results 2981 - 2990 of 3387 in total
  1. Drug

    Indirubin

    go.drugbank.com/drugs/DB12379
    Investigational

    Indirubin is under investigation in clinical trial NCT01735864 (Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  2. Drug

    Lisofylline

    go.drugbank.com/drugs/DB12406
    Investigational

    Lisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  3. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzyme...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2C8 Inhibitors
  4. Drug

    9-aminocamptothecin

    go.drugbank.com/drugs/DB12515
    Investigational

    Aminocamptothecin has been used in trials studying the treatment of Lymphoma, Gastric Cancer, Ovarian Cancer, Esophageal Cancer, and Ovarian Neoplasms, among others.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Mizolastine

    go.drugbank.com/drugs/DB12523
    Approved

    Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  6. Drug

    3,5-diiodothyropropionic acid

    go.drugbank.com/drugs/DB12629
    Investigational

    DITPA has been investigated in Congestive Heart Failure.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Enerisant

    go.drugbank.com/drugs/DB20605
    Experimental

    The usage of the INN stem '-isant' in the name indicates that Enerisant is a histamine H3​ receptor antagonist. Enerisant has a monoisotopic molecular weight of 398.23 Da.

    Categories: P-glycoprotein substrates
  8. Drug

    Besigomsin

    go.drugbank.com/drugs/DB20894
    Experimental

    Besigomsin is a small molecule drug. Besigomsin has a monoisotopic molecular weight of 416.18 Da.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Sorbitan monolaurate

    go.drugbank.com/drugs/DB20157
    Investigational

    Sorbitan monolaurate is a small molecule drug. Sorbitan monolaurate has a monoisotopic molecular weight of 346.24 Da.

    Categories: P-glycoprotein inhibitors
  10. Drug

    Voriconazole

    go.drugbank.com/drugs/DB00582
    ApprovedInvestigational

    Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasiv...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inhibitors